FindTrial
Sign In

Real-world prospective cohort study to explore the efficacy and safety of IL-17i in the treatment of erythrodermic psoriasis and pustular psoriasis

Real-world prospective cohort study to explore the efficacy and safety of IL-17i in the treatment of erythrodermic psoriasis and pustular psoriasis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000041074
Enrollment
Unknown
Registered
2020-12-17
Start date
2021-01-01
Completion date
Unknown
Last updated
2021-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erythrodermic psoriasis, pustular psoriasis

Interventions

IL-17i vs traditional drugs:Nil

Sponsors

The University of Hong Kong-Shenzhen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Be over 18 years old. 2. Erythrodermic psoriasis and pustular psoriasis that have been diagnosed and require systemic treatment. 3. Patients who have been confirmed to receive traditional therapy (Cyclosporin A/Acitretin) or biological agents (IL-17a inhibitors). 4. Have clear contact information. 5. Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. This disease has received systemic treatment or biological agents. 2. Past history of severe heart, liver and kidney, hematopoietic diseases and malignant tumors. 3. Participate in other clinical trials at the same time or end less than 30 days.

Design outcomes

Primary

MeasureTime frame
PASI, GPPASI, BSA;—

Secondary

MeasureTime frame
ESR / CRP;Left ventricular eject fraction;—

Countries

China

Contacts

Public ContactZhang Zhenying

The University of Hong Kong-Shenzhen Hospital

zhangzy@hku-szh.org+86 18307556911

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026